Every Form 4 that QuidelOrtho Corporation (QDEL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow QDEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QDEL filings page.
QuidelOrtho Corp (QDEL) reported that Chief Human Resources Officer Ronald Lee Bowman had restricted stock units convert into common stock on September 15, 2026. 2,566 restricted stock units were exercised into 2,566 shares of common stock, and 921 shares of common stock were delivered to the issuer at $10.63 per share to satisfy tax withholding obligations related to this vesting. Each restricted stock unit represents one share of QuidelOrtho common stock, and no transactions were reported as made under a Rule 10b5-1 trading plan.
QuidelOrtho Corp (QDEL) reported that EVP Global Portfolio Management & Marketing Bryan Michael Hanson had 446 restricted stock units vest on August 15, 2026, converting into 446 shares of common stock. To satisfy related tax withholding obligations, 162 common shares were withheld by the company at $14.30 per share. Following this vesting event, the reported balance of these specific restricted stock units is 0.
Young Micah W reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp granted Chief Financial Officer Micah W. Young 356,555 restricted stock units, each representing one share of common stock. The award vests in three tranches: 118,851 units on July 15, 2027, and 118,852 units on each of July 15, 2028 and July 15, 2029, all held directly.
QuidelOrtho Corp executive Bryan Michael Hanson, EVP Global Portfolio Management & Marketing, released 5,797 restricted stock units into an equal number of common shares on July 1, 2026. To satisfy tax obligations, 2,096 shares were withheld at $18.18 per share. After these transactions, he directly held 7,771 shares of common stock. Footnotes indicate an additional 5,797 RSUs are scheduled to vest on July 1, 2027 and 5,798 on July 1, 2028.
QuidelOrtho Corp director Kenneth J. Widder received several equity-based awards in the form of restricted stock units (RSUs). On June 25, 2026, he was granted 1,997 premium RSUs, 6,656 converted RSUs, and 15,532 equity grant RSUs, each representing one share of common stock. The RSUs were issued in lieu of certain cash retainer and board service fees under a deferred compensation program and vest on a scheduled basis, including full vesting for one grant on June 25, 2027 and four installments of 1,664 shares between June 25, 2026 and March 25, 2027.
Huennekens R Scott reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp director R. Scott Huennekens received a grant of restricted stock units as equity compensation. He was awarded 15,532 restricted stock units representing the right to receive an equal number of shares of QuidelOrtho common stock. These restricted stock units will vest on June 25, 2027, and following the grant he holds 15,532 such units directly.
QuidelOrtho Corp director John R. Chiminski reported awards of restricted stock units (RSUs) linked to common stock. On June 25, 2026, he acquired 1,109 premium RSUs, 5,547 converted RSUs, and 15,532 equity grant RSUs as compensation.
Each RSU represents one share of QuidelOrtho common stock and carries a grant price of $0.00 per unit. One set of RSUs will vest on June 25, 2027, while an additional 1,386 units vested on June 25, 2026 and 1,387 units are scheduled to vest on each of September 25, 2026, December 25, 2026 and March 25, 2027. The RSUs were received in lieu of cash fees under a deferred compensation program for non‑employee directors, with release of vested units following the director’s elected deferral schedule.
Wilkins Joseph D Jr. reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp director receives RSU award
QuidelOrtho Corp director Joseph D. Wilkins Jr. received a grant of 15,532 restricted stock units. Each unit represents the right to receive one share of QuidelOrtho common stock if vesting conditions are met.
The restricted stock units will vest on June 25, 2027. Following this grant, Wilkins holds 15,532 RSUs directly, giving him a future equity stake tied to the company’s share performance once the award vests.
QuidelOrtho Corp director Ann D. Rhoads reported three equity compensation awards in the form of restricted stock units (RSUs). On June 25, 2026, she was granted 369 RSUs labeled as premium units, 3,698 RSUs labeled as converted units, and 15,532 RSUs as an equity grant, each representing one share of common stock when delivered.
The RSUs carry a stated value of $0.00 per unit because they are compensation awards rather than market purchases. One RSU tranche will vest on June 25, 2027, and another tranche is scheduled to vest in stages: 924 shares vested on June 25, 2026, 924 shares will vest on September 25, 2026, 925 shares on December 25, 2026, and 925 shares on March 25, 2027.
The filing explains that these RSUs were received in lieu of cash payments for certain retainer and Board service-related fees under a deferred compensation program for non-employee directors, with release of vested units following the director’s elected deferral schedule.
QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported grants of restricted stock units tied to her board service. On June 25, 2026, she received three awards of premium, converted, and equity grant RSUs covering 1,664, 5,547 and 15,532 units, each representing one share of common stock. Some units vest entirely on June 25, 2027, while 1,386 units vested on June 25, 2026 and additional 1,387-unit tranches will vest on September 25, 2026, December 25, 2026, and March 25, 2027. The RSUs were received in lieu of cash retainers and board-related fees under a deferred compensation program for non-employee directors, with release of vested shares following her elected deferral schedule.
QuidelOrtho Corp director Michael Edward L. received several equity-based compensation awards in the form of restricted stock units on June 25, 2026. These awards are structured as premium, converted, and equity grant restricted stock units, each representing the right to receive one share of QuidelOrtho common stock.
The grants were made at a price of $0.00 per unit as compensation rather than open-market purchases. Footnotes explain that one set of restricted stock units will vest on June 25, 2027, and another set vests in four installments of 878, 878, 878, and 879 units on June 25, 2026, September 25, 2026, December 25, 2026, and March 25, 2027, respectively.
The awards were received in lieu of cash payments for certain retainer and Board of Director service-related fees under a deferred compensation program for participating non-employee directors. Vested units will be released according to the director’s elected deferral schedule, emphasizing that these are compensation-related equity grants rather than discretionary stock trades.
QuidelOrtho Corp director Evelyn S. Dilsaver received a grant of 15,532 restricted stock units (RSUs) as equity compensation. Each RSU corresponds to one share of QuidelOrtho common stock and was awarded at no exercise price. All 15,532 RSUs will vest on June 25, 2027, and her reported direct holdings in this RSU award total 15,532 units after the transaction.
QuidelOrtho Corp director Kenneth F. Buechler received equity-based compensation in the form of restricted stock units (RSUs) on June 25, 2026. He was granted 3,661 premium RSUs, 12,204 converted RSUs, and 15,532 equity grant RSUs, each representing one share of common stock.
The RSUs were awarded in lieu of cash retainer and other Board service-related fees under a deferred compensation program for non-employee directors. One RSU equals one share of QuidelOrtho common stock, with vesting noted to occur on June 25, 2027 for certain awards, and additional tranches of 3,051 shares vesting on June 25, 2026, September 25, 2026, December 25, 2026, and March 25, 2027.
QuidelOrtho Corp director Kenneth J. Widder reported routine equity compensation activity involving restricted stock units. On June 6, 2026, he acquired 273 and 910 shares of common stock at $0.00 per share through grants/awards.
These shares came from the release and conversion of previously reported restricted stock units into common stock, with 273 and 910 units exercised at a $0.00 conversion price. Footnotes explain that the restricted stock unit release had been deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors and occurred according to his elected deferral schedule.
QuidelOrtho Corp director Mary Lake Polan, Ph.D. reported compensation-related equity activity involving restricted stock units and common shares. On June 6, 2026, she exercised a total of 973 restricted stock units at $0.00 per unit, each converting into one share of common stock under the company’s program.
These releases were previously reported awards whose delivery was deferred under QuidelOrtho’s deferred compensation program for non-employee directors. Following these transactions, she held 20,442 shares of common stock directly and 17,353 shares indirectly through an LLC. The filing reflects routine director equity compensation rather than open-market buying or selling.
QuidelOrtho Corp director Kenneth F. Buechler increased his direct stake through equity compensation rather than market buying. On June 6, 2026, he acquired 497 and 1,659 shares of Common Stock at $0.00 per share as grants linked to restricted stock units. These 2,156 shares came from the release and conversion of previously reported restricted stock units under QuidelOrtho's deferred compensation program for participating non-employee directors. Following the transactions, Buechler directly owns 110,906 common shares.
QuidelOrtho Corp director Michael Edward L. reported compensation-related equity activity. He received 1,252 shares of common stock through the release and conversion of restricted stock units on June 6, 2026, at a stated price of $0.00 per share as part of his director compensation. Following these awards and conversions, he holds approximately 29,433 common shares directly. Footnotes explain the restricted stock units were previously reported, each unit represents one common share, and their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors.
QuidelOrtho Corp director Matthew Strobeck increased his direct stake through equity compensation. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at $0.00 per share, previously reported as RSUs.
Following this grant and conversion, he holds 34,604 common shares directly. He also reports indirect positions, including 38,145 shares held by Birchview Fund, LLC, where he has sole voting and dispositive power, and 16,630 shares in UGMA accounts for his children, which he disclaims as beneficially owned.
QuidelOrtho Corp director Kenneth J. Widder reported an equity award tied to restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no cash cost, reflecting a compensation-related grant rather than a market purchase.
Following these transactions, Widder directly holds 43,890 shares of QuidelOrtho common stock. The filing shows an exercise of the corresponding derivative position, leaving no remaining restricted stock units from this grant.
QuidelOrtho Corp director Mary Lake Polan, Ph.D., reported routine equity compensation activity involving restricted stock units and common shares. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at a conversion price of $0.00 per share. These units had been previously reported and each unit represented the right to receive one share of QuidelOrtho common stock. Following the conversion, she held 19,469 shares of common stock directly, while a separate 17,353 shares of common stock were reported as held indirectly through an LLC.
QuidelOrtho Corp director Kenneth F. Buechler reported a compensation-related stock award and vesting of restricted stock units. On May 29, 2026, 6,829 restricted stock units vested and were converted into 6,829 shares of common stock at no exercise price. This is reflected as a grant/acquisition of common shares and an exercise of the corresponding restricted stock unit derivative, leaving no units from that grant outstanding. Following these transactions, Buechler directly holds 108,750 shares of QuidelOrtho common stock.
QuidelOrtho Corp director John R. Chiminski reported routine equity compensation activity. On May 29, 2026, restricted stock units vested and were converted into 6,829 shares of Common Stock, reflecting a previously reported award.
Each restricted stock unit represented one share of QuidelOrtho common stock, and the units vested on May 29, 2026. After this grant and corresponding RSU release, Chiminski directly holds 9,352 shares of QuidelOrtho Common Stock, with no remaining position reported in the related RSUs.
QuidelOrtho Corp director R. Scott Huennekens reported a routine equity compensation event. He acquired 6,829 shares of common stock at a stated price of $0.0000 per share through the release of previously granted restricted stock units. These restricted stock units vested on May 29, 2026 and each unit converted into one share of common stock. Following this vesting and conversion, he directly holds 9,352 shares of QuidelOrtho common stock. The filing shows no open-market purchases or sales, only the vesting and exercise of an equity award.
QuidelOrtho Corp director Joseph D. Wilkins Jr. reported equity compensation activity involving 6,829 shares. He received 6,829 shares of common stock on May 29, 2026 through the release of previously granted restricted stock units, with no sales reported. Following these transactions, he directly owns 18,705 shares of QuidelOrtho common stock. The filing also shows the corresponding exercise of 6,829 restricted stock units into common shares, with no remaining units from this grant after vesting.
QuidelOrtho Corp director Ann D. Rhoads reported equity compensation activity involving restricted stock units. She received 6,829 shares of Common Stock at no cost, related to previously reported restricted stock units. These restricted stock units, each representing one share of common stock, vested on May 29, 2026 and were exercised into common shares the same day. Following these transactions, she holds 23,257 shares of QuidelOrtho common stock directly, with no remaining position in the exercised restricted stock units.
QuidelOrtho Corp director Michael Edward L. received 6,829 shares of Common Stock as a stock award on May 29, 2026, when previously granted restricted stock units vested. These RSUs were exercised into Common Stock, bringing his direct holdings to 28,181 shares, with no open-market buying or selling.
QuidelOrtho Corp director Evelyn S. Dilsaver reported an equity award and related vesting of restricted stock units. On May 29, 2026, she acquired 6,829 shares of common stock at no cost through the release of previously reported restricted stock units. Each unit converted into one share of common stock when the units vested on May 29, 2026. Following these transactions, she directly holds 17,453 shares of QuidelOrtho common stock, and the reported restricted stock unit grant has been fully exercised.
QuidelOrtho Corp director Ann D. Rhoads reported routine equity compensation activity. She received a total of 1,407 shares of common stock on May 22, 2026 through the release of previously reported restricted stock units.
Footnotes state these restricted stock units each convert into one share of common stock and that their release was deferred under QuidelOrtho’s deferred compensation program for participating non-employee directors, occurring according to her elected deferral schedule. The filing shows no open‑market purchases or sales, only grants and conversions of equity awards.
QuidelOrtho Corp President and CEO Brian J. Blaser reported routine equity compensation activity. On May 15, 20,759 restricted stock units converted into an equal number of common shares, reflecting a scheduled vesting.
To cover tax obligations from this vesting, 10,252 common shares were withheld at $10.32 per share, a tax-withholding disposition rather than an open-market sale. Following these transactions, he holds 35,649 common shares directly and 40,073 common shares indirectly through a trust. Footnotes note that 20,759 shares vested on each of May 15, 2025 and May 15, 2026, with another 20,759 scheduled to vest on May 15, 2027.
QuidelOrtho Corp executive Bryan Michael Hanson, EVP Global Portfolio Management & Marketing, reported routine equity compensation activity. On April 26, 2026, 1,459 restricted stock units vested and converted into the same number of common shares, as previously disclosed on a Form 3. To cover related tax withholding obligations, 528 common shares were withheld by the company at a reference price of $11.59 per share, a non-market disposition. Following these transactions, Hanson directly holds 4,070 shares of QuidelOrtho common stock.
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported routine equity compensation activity involving restricted stock units and related tax withholding. On April 26, 2026, 1,946 restricted stock units were released and converted into the same number of common shares at no cost, increasing his direct holdings.
To cover tax withholding obligations tied to this vesting, 699 common shares were withheld and disposed of at a value of $11.59 per share, a non‑market, tax-driven transaction. After these transactions, McLellan directly held 22,497 shares of QuidelOrtho common stock.
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported routine equity compensation activity. On April 22, 2026, 3,238 restricted stock units vested and were released into an equal number of common shares. The company withheld 1,162 of those shares at a price of $11.90 per share to cover tax obligations, a non‑market disposition. After these transactions, McLellan directly held 21,250 common shares. An additional 3,238 restricted stock units are scheduled to vest on April 22, 2027.
QuidelOrtho Corp EVP Bryan Michael Hanson reported the vesting and settlement of 3,508 restricted stock units into the same number of common shares on April 22, 2026. Of these, 1,269 shares were withheld at $11.9000 per share to cover tax obligations. After these transactions, he directly holds 3,139 shares of common stock.
SISITSKY NATHANIEL reported acquisition or exercise transactions in this Form 4 filing.
QuidelOrtho Corp granted its Chief Legal Officer, Nathaniel Sisitksy, new equity awards reported as compensation. He received 73,434 non-qualified stock options exercisable at $17.49 per share, expiring on April 15, 2036, covering 73,434 shares of common stock. He was also granted 73,435 restricted stock units, each representing one share of common stock. For these awards, 24,478 shares are scheduled to vest in equal installments on April 15, 2027 and April 15, 2028, with 24,479 shares vesting on April 15, 2029, and another schedule provides 24,478 shares vesting in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported routine equity compensation activity involving restricted stock units and related tax withholding. On the transaction date, 4,925 restricted stock units were released, converting into 4,925 shares of common stock as part of previously reported awards.
Of these shares, 1,519 were withheld by the company at $14.78 per share to satisfy tax withholding obligations tied to the RSU release, which is not an open-market sale. Following these transactions, Busky held 44,818 shares of common stock directly and 10,290 shares indirectly through a trust.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an amended insider transaction reflecting an open-market purchase of 3,370 shares of common stock on February 13, 2026, acquired indirectly through a trust at a weighted average price of $23.6623 per share.
The amendment corrects the pricing details, noting a purchase price range from $23.0150 to $23.6750 per share. Following these transactions, Busky’s indirect holdings held by a trust total 10,290 shares, and his direct ownership stands at 41,412 shares of QuidelOrtho common stock.
Strobeck Matthew reported open-market purchase transactions in a Form 4 filing for QDEL. The filing lists transactions totaling 10,000 shares at a weighted average price of $23.96 per share. Following the reported transactions, holdings were 27,775 shares.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an open‑market purchase of common stock. On February 13, 2026, a trust associated with him bought 3,370 shares at $23.6623 per share, bringing its indirect holdings to 10,290 shares and his direct holdings to 41,412 shares.
QuidelOrtho Corp President and CEO Brian J. Blaser reported an indirect open-market purchase of common stock through a trust associated with him. On February 13, 2026, the trust bought 10,540 shares at a weighted average price of $23.5921 per share, within a range of $23.4200 to $23.9400.
After this transaction, the trust held 40,073 shares of QuidelOrtho common stock indirectly for Blaser, while he also held 25,142 shares directly. The filing notes that detailed trade-by-trade pricing is available upon request from the reporting person.
QuidelOrtho Corp Chief Legal Officer reports equity award vesting and tax withholding. On February 8, 2026, Michelle A. Hodges had 3,198 restricted stock units convert into an equal number of common shares at a stated price of $0, increasing her directly held stake.
In connection with this vesting, 1,148 common shares were disposed of at $29.10 per share to cover tax withholding obligations, rather than being an open-market sale. After these transactions, Hodges directly owned 41,605 shares of QuidelOrtho common stock.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported equity compensation activity involving restricted stock units and common shares. On February 8, 2026, 5,968 restricted stock units were converted into 5,968 shares of common stock at a stated price of $0.
In connection with this release, 1,806 common shares at $29.1 per share were withheld by the issuer to satisfy tax withholding obligations, leaving Busky with 41,412 common shares held directly. He also reports 6,920 common shares held indirectly by a trust.
The filing notes that 5,968 shares vested on each of February 8, 2025 and February 8, 2026, and 5,969 additional shares are scheduled to vest on February 8, 2027, reflecting an ongoing multi‑year restricted stock unit vesting schedule.
QuidelOrtho Corporation’s Chief Human Resources Officer, Ronald Lee Bowman, reported equity awards on January 30, 2026. He received 36,152 restricted stock units, each representing one share of common stock, and 36,150 non-qualified stock options with a $27.17 exercise price expiring January 30, 2036.
Of the restricted stock units, 12,050 shares will vest on January 30, 2027, and the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029. The 36,150 stock options will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029. All holdings are reported as directly owned.
QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported multiple equity compensation transactions. On January 30, 2026, he received 36,152 restricted stock units and 36,150 non-qualified stock options with a $27.17 exercise price, vesting in tranches from 2027 to 2029. On January 31, 2026, several blocks of restricted stock units converted into common stock, increasing his direct holdings, while the company withheld shares at $27.17 per share to cover tax obligations. After these transactions, he directly owned 19,174 shares of common stock, plus the newly granted RSUs and options.
QuidelOrtho Corporation executive Jonathan Philip Siegrist, EVP of R&D & CTO, reported new equity awards in the form of restricted stock units (RSUs) and stock options. On January 30, 2026, he received 36,152 RSUs, each representing one share of QuidelOrtho common stock, and 36,150 non-qualified stock options with a $27.17 exercise price.
For the RSUs, 12,050 shares are scheduled to vest on January 30, 2027, and the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029. The 36,150 stock options will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029. All awards are reported as directly owned by Siegrist.
QuidelOrtho Corporation’s Chief Legal Officer, Michelle A. Hodges, reported multiple equity transactions. On January 30, 2026, she received 38,562 restricted stock units (RSUs) and 38,561 non-qualified stock options with an exercise price of $27.17, with vesting scheduled between 2027 and 2029 and the options expiring in 2036.
On January 31, 2026, previously granted RSUs for 1,610 and 1,814 shares converted into the same number of common shares at no cost. The company withheld 578 and 651 shares at $27.17 per share to cover tax obligations. After these transactions, she directly held 39,555 shares of common stock.
QuidelOrtho Corporation reported an equity compensation grant to its Chief Financial Officer, Joseph M. Busky. On January 30, 2026, he was awarded 29,444 restricted stock units (RSUs), each representing one share of QuidelOrtho common stock, at a grant price of $0 as part of his compensation.
According to the vesting schedule, 9,814 shares will vest on January 30, 2027. The remaining 19,630 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning Busky’s incentives with the company’s multi‑year performance.
QuidelOrtho Corporation President and CEO Brian J. Blaser received a grant of 213,470 restricted stock units on January 30, 2026. Each unit represents the right to receive one share of QuidelOrtho common stock.
According to the vesting schedule, 71,156 shares will vest on January 30, 2027. The remaining 142,314 shares will vest in equal installments on January 30, 2028 and January 30, 2029, aligning the CEO’s compensation with longer-term company performance.
QuidelOrtho Corporation executive Jonathan Philip Siegrist, EVP of R&D & CTO, reported equity compensation activity involving restricted stock units and common shares. On January 29, 2026, 2,448 restricted stock units vested and converted into the same number of QuidelOrtho common shares at $0 per share.
To cover tax withholding on this vesting, 1,009 common shares were disposed of at a price of $27.41 per share through share withholding. After these transactions, Siegrist directly owned 13,419 common shares and held 4,898 restricted stock units, which are scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corporation’s Chief Operations Officer Philip D. McLellan reported routine equity compensation activity. On January 29, 2026, 4,897 restricted stock units vested and converted into an equal number of common shares at $0 per share. To cover tax withholding on this release, 2,017 common shares were withheld at $27.41 per share, leaving McLellan with 16,184 common shares held directly. After this vesting, he also holds 9,796 restricted stock units, scheduled to vest in equal installments on January 29, 2027 and January 29, 2028.
QuidelOrtho Corp’s Chief Legal Officer, Michelle A. Hodges, reported equity award activity involving restricted stock units and common shares. On January 29, 2026, 7,836 restricted stock units converted into 7,836 shares of common stock at $0, reflecting the vesting of a prior award.
To cover tax withholding on this release, 3,072 common shares were withheld at a price of $27.41 per share. After these transactions, Hodges directly owned 37,360 shares of QuidelOrtho common stock and 15,673 restricted stock units, each representing the right to receive one share if and when it vests.